|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3600 USD | 0.00% |
|
-5.29% | -43.68% |
| 05-13 | Cytosorbents Corporation, Q1 2026 Earnings Call, May 13, 2026 | |
| 05-13 | Cytosorbents Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Company Valuation: Cytosorbents Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182.2 | 67.64 | 57.95 | 49.76 | 40.14 | 22.61 | - | - |
| Change | - | -62.87% | -14.31% | -14.14% | -19.32% | -43.69% | - | - |
| Enterprise Value (EV) | 182.2 | 67.64 | 57.95 | 49.76 | 40.14 | 22.61 | 22.61 | 22.61 |
| Change | - | -62.87% | -14.31% | -14.14% | -19.32% | -43.69% | 0% | 0% |
| P/E | -7.35x | -2.07x | -1.73x | -2.39x | -4.92x | -1.95x | 12x | 6x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.1x | 0.1x | 0.1x | 0.1x | -0x | -0x | 0x |
| Capitalization / Revenue | 4.22x | 1.95x | 1.59x | 1.27x | 1.08x | 0.59x | 0.48x | 0.44x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 0.59x | 0.48x | 0.44x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -3.21x | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -2.57x | 9.53x | 4.64x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.57 | -0.75 | -0.64 | -0.38 | -0.13 | -0.185 | 0.03 | 0.06 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 43.17 | 34.69 | 36.35 | 39.2 | 37.06 | 38.26 | 47.12 | 51.6 |
| EBITDA 1 | -15.81 | -26.84 | -26.05 | -11.46 | -13.3 | -7.046 | - | - |
| EBIT 1 | -22.74 | -31.52 | -31.21 | -16.79 | -14.24 | -8.78 | 2.373 | 4.869 |
| Net income 1 | -24.56 | -32.81 | -28.51 | -20.72 | -8.198 | -11.74 | 2.373 | 4.869 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 4.1900 | 1.5500 | 1.1100 | 0.9100 | 0.6392 | 0.3600 | 0.3600 | 0.3600 |
| Nbr of stocks (in thousands) | 43,476 | 43,636 | 52,212 | 54,680 | 62,804 | 62,795 | - | - |
| Announcement Date | 3/8/22 | 3/9/23 | 3/14/24 | 3/31/25 | 3/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.95x | - | - | - | 22.61M | |
| 28.31x | 5.12x | 19.63x | 0.32% | 211B | |
| 31.99x | 5.88x | 18.61x | 0.77% | 135B | |
| 36.98x | 9.57x | 21.13x | -.--% | 119B | |
| 15.82x | 3.35x | 10.81x | -.--% | 65.77B | |
| 31.71x | 6.5x | 20.56x | -.--% | 47.58B | |
| 18.58x | 2.14x | 11.09x | 2.82% | 44.44B | |
| 26.95x | 5.36x | 18.32x | 0.74% | 39.14B | |
| 45.41x | 6.34x | 19.47x | -.--% | 36.79B | |
| 41.41x | 6.53x | 23.25x | -.--% | 29.37B | |
| Average | 27.52x | 5.64x | 18.10x | 0.52% | 72.81B | |
| Weighted average by Cap. | 30.23x | 5.87x | 18.50x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CTSO Stock
- Valuation Cytosorbents Corporation
Select your edition
All financial news and data tailored to specific country editions
